Early Initiation of Irbesartan Therapy Improves Cardiac and Kidney Function in Hypertensive Patients. Is This a Novel Pathway to Reduce HFpEF Incidence?

Research Article

Austin Cardio & Cardiovasc Case Rep. 2023; 8(1): 1050.

Early Initiation of Irbesartan Therapy Improves Cardiac and Kidney Function in Hypertensive Patients. Is This a Novel Pathway to Reduce HFpEF Incidence?

Nikolaos PE Kadoglou¹*; Sofia Arapi²; Anastasia Perpinia²; Ioannis Nektarios Karavidas²; Apostolos Karavidas²

1Medical School, University of Cyprus, Nicosia, Cyprus

2General Hospital of Athens “G. Gennimatas”, Athens, Greece

*Corresponding author: Nikolaos PE Kadoglou 215/6 Old road Lefkosias-Lemesou, CY-2029, Aglantzia, Nicosia, Cyprus. Tel: +357 22895260 Email: [email protected] [email protected]

Received: February 20, 2023 Accepted: April 03, 2023 Published: April 10, 2023

Abstract

We evaluated the impact of irbesartan (150mg once/day for 6 months) on kidney function, echocardiographic parameters and pre-clinical atherosclerosis indexes in 33 patients with newly onset of hypertension and without overt kidney dysfunction (Hypertensive Group–HTG). 15 age- and sex-matched, normotensive, healthy individuals (Normotensive Group–NTG) served as controls, without receiving any medication. After 6 months, HTG further improved its kidney function, flow-mediated dilation, diastolic function, left ventricle mass and left atrium volume implicating a cardio and reno-protective action in patients with newly onset of hypertension.

Introduction

Angiotensin II Receptor Blockers (ARBs), are well-known anti-hypertensive medications with favourable effects on cardiac function and structure in hypertensive patients [1]. Meta-analyses support the reno-protective effects of ARBs, since they might maintain the residual kidney function in dialysis patients [2] or may slow down the progression of early kidney dysfunction to end-stage Chronic Kidney Disease (CKD) [3]. Current international guidelines have recommended the use of Angiotensin Converting Enzyme-inhibitors (ACEi) and alternatively ARBs, in preference to other anti hypertensive agents for treating hypertensive patients with mild CKD [4]. Notably, previous studies have examined the impact of ARBs on kidney function focusing hypertensive patients with established CKD of any degree.

The aim of the present study was to evaluate the impact of irbesartan, an ARB family member, on kidney function, echocardiographic parameters and pre-clinical atherosclerosis indexes in patients with newly onset of hypertension and without overt kidney dysfunction.

Methods

In our non-randomized study, we enrolled 33 patients (51.5% men), with newly onset hypertension (hypertensive group – HTG). Those patients had previously experienced side effects from ACEi and were the last month free from any chronic medication. A small group of 15 age- and sex-matched, normotensive, healthy individuals (Normotensive Group–NTG) served as controls. HTG received irbesartan 150mg once/day for 6 months and was evaluated at baseline and at the end. Evaluation included: Echocardiogram (cavities size and function, mitral inflow pattern, Left-Ventricle (LV) mass, Tissue Doppler Imaging - TDI), brachial artery Flow-Mediated Dilatation (FMD), Carotid artery Intima-Media Thickness (CIMT), and blood samples analysis (glucose, lipid, kidney profiles).

FMD Measurement

All tests were performed after overnight fasting. We inflated a blood pressure cuff, placed on the proximal forearm, 50mmHg above the systolic blood pressure for 5 minutes and we then deflated. We acquired and analyzed end-diastolic images of the brachial artery at baseline and 90 seconds after cuff deflation using the 7.5-mHz linear-array transducer (General Electric Logiq700, Riverside, USA). FMD was calculated by subtracting brachial artery average diameter at baseline from that at 90 seconds. Relative FMD was expressed as the percentage change from baseline (% FMD), divided by the baseline FMD.

Measurement of Carotid IMT

We performed a diagnostic high-resolution B-mode ultrasound of both carotids at baseline and at the end of the study. End-diastolic, B-mode images from longitudinal segments of each Common Carotid Artery (CCA), at 1-cm distance from the bifurcation on both walls, were allocated for CIMT measurement. We averaged CIMT measurements made over six cardiac cycles of each CCA and we then obtained the mean of left and right CCA IMT.

Statistical Analysis

Normally distributed continuous variables were expressed as the mean value ±SD and were compared within groups (paired-samples t-test) or between groups (student’s t-test). Continuous variables with abnormal distribution presented as median with maximum and minimum values and Wilcoxon signed-rank test was used to assess within group differences. We considered a two-tailed p<0.05 as statistically significant. We used computer software package SPSS (version 23.0; SPSS Inc, Chicago, IL, USA) for statistical analysis.

Results

In HTG, the mean age was 61 years (33 years–78 years) and significant proportions had hyperlipidemia (42.4%), diabetes (15.2%) or obesity (21.2%) (BMI >30kg/m²), which did not alter significantly alter throughout the study. 6-month irbesartan treatment led to significant amelioration in both creatinine (p=0.008) and GFR (p=0.05) levels. With the exception of reduced cholesterol, the rest of biochemical parameters remained unaltered throughout the study.

Regarding echocardiographic parameters, irbesartan therapy significantly improved diastolic function as assessed by: deceleration time (p=0.001), tissue doppler imaging velocities (p=0.001), mitral E wave velocity (p=0.009). Besides this, there was a considerable reduction in LV mass (p=0.025), posterior wall thickness (p=0.043) and left atrial volume (p=0.02) within the irbesartan-treated group. That effect was associated with considerable increase in FMD after long-term irbesartan administration (p=0.006). In contrast, CIMT measurements did not change at all. All results are depicted in (Table 1a & b).

Citation: Kadoglou NPE, Arapi S, Perpinia A, Karavidas IN, Karavidas A. Early Initiation of Irbesartan Therapy Improves Cardiac and Kidney Function in Hypertensive Patients. Is This a Novel Pathway to Reduce HFpEF Incidence?. Austin Cardio & Cardiovasc Case Rep. 2023; 8(1): 1051.